View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsRubius Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Rubius Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-4.5%자사주 매입 수익률총 주주 수익률-4.5%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Feb 07Rubius Therapeutics Receives Non-Compliance Letter from NasdaqOn February 6, 2023, Rubius Therapeutics, Inc. was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) as of January 23, 2023, and the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, the Company would be delisted at the opening of business on February 15, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”) to address the deficiencies and present a plan to regain compliance. The Company plans to timely request a hearing before the Panel, which request will stay any further delisting action by the Staff at least pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel. The Company’s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process. As previously disclosed, on July 27, 2022, the Company received written notice from the Staff indicating that, based upon the closing bid price for the Company’s common stock for the previous 30 consecutive business days, the Company no longer satisfied the minimum bid price requirement for continued listing on The Nasdaq Global Select Market and, in accordance with the Nasdaq Listing Rules, was afforded a 180-calendar day grace period, through January 23, 2023 to regain compliance with the rule. The Company did not regain compliance with minimum bid price requirement by January 23, 2023 and, given the Staff’s separate determination that the Company is a public shell, the Staff did not grant the Company a second grace period to do so.Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Bob Langer is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Price Target Changed • Sep 13Price target increased to US$7.63Up from US$6.80, the current price target is an average from 4 analysts. New target price is 723% above last closing price of US$0.93. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Aug 10Price target increased to US$10.33Up from US$7.00, the current price target is an average from 5 analysts. New target price is 1,209% above last closing price of US$0.79. Stock is down 97% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year.Seeking Alpha • Aug 09Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03Rubius Therapeutics press release (NASDAQ:RUBY): Q2 GAAP EPS of -$0.49 beats by $0.03. cash, cash equivalents and investments were $140.7 million공시 • Jul 28Rubius Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022Rubius Therapeutics, Inc. announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 09, 2022Seeking Alpha • Jun 19Rubius: Poor Data, Punishing Environment, Beaten StockRubius presented unconvincing data at AACR. The stock is down 80% in just 3 months. They have some cash, but it may not last them long enough.Price Target Changed • May 12Price target decreased to US$7.60Down from US$8.67, the current price target is an average from 5 analysts. New target price is 513% above last closing price of US$1.24. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$2.11 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Apr 27Price target decreased to US$8.67Down from US$20.00, the current price target is an average from 5 analysts. New target price is 381% above last closing price of US$1.80. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Apr 12Price target decreased to US$9.40Down from US$20.00, the current price target is an average from 5 analysts. New target price is 300% above last closing price of US$2.35. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Apr 09Price target increased to US$23.00Up from US$21.33, the current price target is an average from 5 analysts. New target price is 621% above last closing price of US$3.19. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$2.35 next year compared to a net loss per share of US$2.23 last year.Seeking Alpha • Mar 21Rubius Looks Attractive Before AACR Data ReadoutLast year's AACR data saw impressive movement for the stock. This year, expectations are somewhat numbed. However, I still expect some small spike.Price Target Changed • Mar 02Price target increased to US$23.00Up from US$21.33, the current price target is an average from 4 analysts. New target price is 389% above last closing price of US$4.70. Stock is down 52% over the past year. The company is forecast to post a net loss per share of US$2.39 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Feb 10Price target decreased to US$21.33Down from US$24.50, the current price target is an average from 5 analysts. New target price is 242% above last closing price of US$6.23. Stock is down 57% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year.Price Target Changed • Feb 02Price target decreased to US$23.33Down from US$25.67, the current price target is an average from 5 analysts. New target price is 246% above last closing price of US$6.75. Stock is down 42% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year.Price Target Changed • Dec 24Price target decreased to US$25.67Down from US$28.67, the current price target is an average from 5 analysts. New target price is 134% above last closing price of US$10.98. Stock is up 37% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year.분석 기사 • Oct 28Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?Today we will run through one way of estimating the intrinsic value of Rubius Therapeutics, Inc. ( NASDAQ:RUBY ) by...Seeking Alpha • Jul 11Our Read On Rubius TherapeuticsToday, we take our first in-depth look at Rubius Therapeutics which has developed a new class of cellular therapies called Red Cell Therapeutics. The company's pipeline has several candidates in development and Rubius recently addressed its current funding needs. A full investment analysis follows in the paragraphs below.Breakeven Date Change • May 14Forecast to breakeven in 2025The 4 analysts covering Rubius Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.0m in 2025. Average annual earnings growth of 24% is required to achieve expected profit on schedule.Recent Insider Transactions Derivative • Mar 18Insider exercised options and sold US$313k worth of stockOn the 15th of March, Maiken Keson-Brookes exercised 25k options at a strike price of around US$7.70 and sold these shares for an average price of US$20.24 per share. This trade did not impact their existing holding. As of today, Maiken currently holds no shares directly. Company insiders have collectively sold US$86k more than they bought, via options and on-market transactions in the last 12 months.Is New 90 Day High Low • Mar 10New 90-day high: US$15.01The company is up 95% from its price of US$7.71 on 09 December 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.분석 기사 • Feb 25Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...Price Target Changed • Feb 25Price target raised to US$13.25Up from US$11.50, the current price target is an average from 5 analysts. The new target price is 19% above the current share price of US$11.18. As of last close, the stock is up 38% over the past year.Recent Insider Transactions Derivative • Feb 12Executive Chairman notifies of intention to sell stockDavid Epstein intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 8th of February. If the sale is conducted around the recent share price of US$14.93, it would amount to US$3.0m. Since March 2020, David has owned 4.82m shares directly. Company insiders have collectively bought US$285k more than they sold, via options and on-market transactions, in the last 12 months.Is New 90 Day High Low • Jan 26New 90-day high: US$10.00The company is up 115% from its price of US$4.65 on 27 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 27% over the same period.Price Target Changed • Jan 20Price target raised to US$10.29Up from US$9.43, the current price target is an average from 5 analysts. The new target price is 8.2% above the current share price of US$9.51. As of last close, the stock is up 12% over the past year.Is New 90 Day High Low • Jan 08New 90-day high: US$8.83The company is up 62% from its price of US$5.45 on 09 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.Is New 90 Day High Low • Dec 15New 90-day high: US$8.73The company is up 72% from its price of US$5.09 on 15 September 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Nov 24New 90-day high: US$5.92The company is up 17% from its price of US$5.05 on 25 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 21New 90-day low: US$4.62The company is down 18% from its price of US$5.63 on 23 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Sep 24New 90-day low: US$4.75The company is down 20% from its price of US$5.93 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 RUBY 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: RUBY 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Rubius Therapeutics 배당 수익률 vs 시장RUBY의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (RUBY)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.3%분석가 예측 (RUBY) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 RUBY 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 RUBY 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 RUBY 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: RUBY 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/01/03 01:24종가2023/12/29 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Rubius Therapeutics, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael SchmidtGuggenheim Securities, LLCAndrew FeinH.C. Wainwright & Co.Michael YeeJefferies LLC2명의 분석가 더 보기
공시 • Feb 07Rubius Therapeutics Receives Non-Compliance Letter from NasdaqOn February 6, 2023, Rubius Therapeutics, Inc. was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) as of January 23, 2023, and the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, the Company would be delisted at the opening of business on February 15, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”) to address the deficiencies and present a plan to regain compliance. The Company plans to timely request a hearing before the Panel, which request will stay any further delisting action by the Staff at least pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel. The Company’s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process. As previously disclosed, on July 27, 2022, the Company received written notice from the Staff indicating that, based upon the closing bid price for the Company’s common stock for the previous 30 consecutive business days, the Company no longer satisfied the minimum bid price requirement for continued listing on The Nasdaq Global Select Market and, in accordance with the Nasdaq Listing Rules, was afforded a 180-calendar day grace period, through January 23, 2023 to regain compliance with the rule. The Company did not regain compliance with minimum bid price requirement by January 23, 2023 and, given the Staff’s separate determination that the Company is a public shell, the Staff did not grant the Company a second grace period to do so.
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Bob Langer is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Price Target Changed • Sep 13Price target increased to US$7.63Up from US$6.80, the current price target is an average from 4 analysts. New target price is 723% above last closing price of US$0.93. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Aug 10Price target increased to US$10.33Up from US$7.00, the current price target is an average from 5 analysts. New target price is 1,209% above last closing price of US$0.79. Stock is down 97% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year.
Seeking Alpha • Aug 09Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03Rubius Therapeutics press release (NASDAQ:RUBY): Q2 GAAP EPS of -$0.49 beats by $0.03. cash, cash equivalents and investments were $140.7 million
공시 • Jul 28Rubius Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022Rubius Therapeutics, Inc. announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 09, 2022
Seeking Alpha • Jun 19Rubius: Poor Data, Punishing Environment, Beaten StockRubius presented unconvincing data at AACR. The stock is down 80% in just 3 months. They have some cash, but it may not last them long enough.
Price Target Changed • May 12Price target decreased to US$7.60Down from US$8.67, the current price target is an average from 5 analysts. New target price is 513% above last closing price of US$1.24. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$2.11 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Apr 27Price target decreased to US$8.67Down from US$20.00, the current price target is an average from 5 analysts. New target price is 381% above last closing price of US$1.80. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Apr 12Price target decreased to US$9.40Down from US$20.00, the current price target is an average from 5 analysts. New target price is 300% above last closing price of US$2.35. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Apr 09Price target increased to US$23.00Up from US$21.33, the current price target is an average from 5 analysts. New target price is 621% above last closing price of US$3.19. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$2.35 next year compared to a net loss per share of US$2.23 last year.
Seeking Alpha • Mar 21Rubius Looks Attractive Before AACR Data ReadoutLast year's AACR data saw impressive movement for the stock. This year, expectations are somewhat numbed. However, I still expect some small spike.
Price Target Changed • Mar 02Price target increased to US$23.00Up from US$21.33, the current price target is an average from 4 analysts. New target price is 389% above last closing price of US$4.70. Stock is down 52% over the past year. The company is forecast to post a net loss per share of US$2.39 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Feb 10Price target decreased to US$21.33Down from US$24.50, the current price target is an average from 5 analysts. New target price is 242% above last closing price of US$6.23. Stock is down 57% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year.
Price Target Changed • Feb 02Price target decreased to US$23.33Down from US$25.67, the current price target is an average from 5 analysts. New target price is 246% above last closing price of US$6.75. Stock is down 42% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year.
Price Target Changed • Dec 24Price target decreased to US$25.67Down from US$28.67, the current price target is an average from 5 analysts. New target price is 134% above last closing price of US$10.98. Stock is up 37% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year.
분석 기사 • Oct 28Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?Today we will run through one way of estimating the intrinsic value of Rubius Therapeutics, Inc. ( NASDAQ:RUBY ) by...
Seeking Alpha • Jul 11Our Read On Rubius TherapeuticsToday, we take our first in-depth look at Rubius Therapeutics which has developed a new class of cellular therapies called Red Cell Therapeutics. The company's pipeline has several candidates in development and Rubius recently addressed its current funding needs. A full investment analysis follows in the paragraphs below.
Breakeven Date Change • May 14Forecast to breakeven in 2025The 4 analysts covering Rubius Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.0m in 2025. Average annual earnings growth of 24% is required to achieve expected profit on schedule.
Recent Insider Transactions Derivative • Mar 18Insider exercised options and sold US$313k worth of stockOn the 15th of March, Maiken Keson-Brookes exercised 25k options at a strike price of around US$7.70 and sold these shares for an average price of US$20.24 per share. This trade did not impact their existing holding. As of today, Maiken currently holds no shares directly. Company insiders have collectively sold US$86k more than they bought, via options and on-market transactions in the last 12 months.
Is New 90 Day High Low • Mar 10New 90-day high: US$15.01The company is up 95% from its price of US$7.71 on 09 December 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.
분석 기사 • Feb 25Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Price Target Changed • Feb 25Price target raised to US$13.25Up from US$11.50, the current price target is an average from 5 analysts. The new target price is 19% above the current share price of US$11.18. As of last close, the stock is up 38% over the past year.
Recent Insider Transactions Derivative • Feb 12Executive Chairman notifies of intention to sell stockDavid Epstein intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 8th of February. If the sale is conducted around the recent share price of US$14.93, it would amount to US$3.0m. Since March 2020, David has owned 4.82m shares directly. Company insiders have collectively bought US$285k more than they sold, via options and on-market transactions, in the last 12 months.
Is New 90 Day High Low • Jan 26New 90-day high: US$10.00The company is up 115% from its price of US$4.65 on 27 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 27% over the same period.
Price Target Changed • Jan 20Price target raised to US$10.29Up from US$9.43, the current price target is an average from 5 analysts. The new target price is 8.2% above the current share price of US$9.51. As of last close, the stock is up 12% over the past year.
Is New 90 Day High Low • Jan 08New 90-day high: US$8.83The company is up 62% from its price of US$5.45 on 09 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.
Is New 90 Day High Low • Dec 15New 90-day high: US$8.73The company is up 72% from its price of US$5.09 on 15 September 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Nov 24New 90-day high: US$5.92The company is up 17% from its price of US$5.05 on 25 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 21New 90-day low: US$4.62The company is down 18% from its price of US$5.63 on 23 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Sep 24New 90-day low: US$4.75The company is down 20% from its price of US$5.93 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.